2022

Sayed S, Sidorova OA, Hennig A, Augsburg M, Cortes Vesga CP, Abohawya M, Schmitt LT, Sürün D, Stange DE, Mircetic J, Buchholz F (2022). Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing. Cancer Res. 2022 Jul 8;can.21.2519. doi: 10.1158/0008-5472.CAN-21-2519. PubMed

Ding L, Schmitt LT, Brux M, Sürün D, Augsburg M, Lansing F, Mircetic J, Theis M, Buchholz F (2022). DNA methylation-independent long-term epigenetic silencing with dCRISPR/Cas9 fusion proteins. Life Sci Alliance. 2022 Mar 14;5(6):e202101321. doi: 10.26508/lsa.202101321. Print 2022 Jun. PubMed

Sidorova OA, Sayed S, Paszkowski-Rogacz M, Seifert M, Camgöz A, Roeder I, Bornhäuser M, Thiede C, Buchholz F (2022). RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Cells. 2022 Mar 2;11(5):854. doi: 10.3390/cells11050854. PubMed

Guillén-Pingarrón C, Guillem-Gloria PM, Soni A, Ruiz-Gómez G, Augsburg M, Buchholz F, Anselmi M, Pisabarro MT (2022). Conformational dynamics promotes disordered regions from function-dispensable to essential in evolved site-specific DNA recombinases. Comput Struct Biotechnol J. 2022 Jan 22;20:989-1001. doi: 10.1016/j.csbj.2022.01.010. eCollection 2022. PubMed

Lansing F, Mukhametzyanova L, Rojo-Romanos T, Iwasawa K, Kimura M, Paszkowski-Rogacz M, Karpinski J, Grass T, Sonntag J, Schneider PM, Günes C, Hoersten J, Schmitt LT, Rodriguez-Muela N, Knöfler R, Takebe T, Buchholz F (2022). Correction of a Factor VIII genomic inversion with designer-recombinases. Nature Communications volume 13, Article number: 422. doi: 10.1038/s41467-022-28080-7. PubMed